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Background: Variants in the FTO gene have been associated with obesity in children, but this association has not
been shown with other biomarkers. We assessed the association of 52 FTO polymorphisms, spanning the whole
gene, with obesity and estimated the influence of these polymorphisms on anthropometric, clinical and metabolic
parameters as well as inflammation and cardiovascular disease (CVD) risk biomarkers among Spanish children.
Methods: A multicentre case–control study was conducted in 534 children (292 obese and 242 with normal-BMI).
Anthropometric, clinical, metabolic, inflammation and CVD risk markers were compared using the Student’s t-test
for unpaired samples. The genotype relative risk was assessed by comparing the obese and normal-BMI group,
calculating the odds ratio. The association of each SNP with phenotypic parameters was analysed using either
logistic or linear regression analysis.
Results: All anthropometric, clinical and metabolic factors as well as inflammatory and CVD risk biomarkers were
higher in the obese than in the normal-BMI group, except adiponectin and HDL-c that were lower, and glucose,
LDL-c, and metalloproteinase-9 that did not show difference. Four polymorphisms (rs9935401, rs9939609, rs9928094
and rs9930333) were positively associated with obesity and in linkage disequilibrium between each other; the
haplotype including the risk alleles of these polymorphisms showed a high risk for obesity. The rs8061518 was
negatively associated with obesity and the haplotype including this SNP and rs3826169, rs17818902 and rs7190053
showed a decreased risk for obesity. Additionally, the rs8061518 was associated with weight, diastolic blood
pressure, insulin, homeostatic model assessment of insulin resistance, leptin, and active plasminogen inhibitor
activator-1 after sex and age adjustment; however, after an additional BMI adjustment, this polymorphism remained
associated only with leptin.
Conclusions: We validated the previous reported association of genetic variability in intron 1 of the FTO gene with
the risk of obesity and found no association with other related traits in this region of the gene. We have observed
strong statistical evidence for an association of rs8061518 in intron 3 of the gene with decreased risk of obesity and
low concentration of leptin.
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Obesity is described as a disease with genetic and environ-
mental influence that may lead to several comorbidities
such as type 2 diabetes, cardiovascular diseases (CVD),
metabolic syndrome (MS) and respiratory abnormalities
among others [1,2]. Since the discovery of its association
with variants in intron 1 of the fat mass and obesity associ-
ated (FTO) gene [3-5], many studies have been conducted
to replicate this finding, to identify new variants, to clarify
the biological function of the protein encoded and to ex-
plain its role in the origin and/or development of obesity
[6]. FTO was initially associated with type 2 diabetes melli-
tus in European descent population [3]; however, simultan-
eous studies showed that the association was mediated by
its effect on obesity [4,5]. This association with obesity also
has been observed in different populations as Europeans
[4,5,7-9], Asians [10,11], African Americans [12,13] and
Hispanic Americans [13]. Among the identified polymor-
phisms, the rs9939609 is one of the most strongly associ-
ated with common obesity [10,14,15]; however, several
other single nucleotide polymorphism (SNP)s in the first
intron of the FTO gene that are in linkage disequilibrium
(LD) with rs9939609 showed similar effects on both child-
hood [4,7,16] and adult obesity [3,4].
It is common to observe clinical, metabolic and CVD
risk factors in many, but not all obese children. How-
ever, few studies include a large number of biomarkers
of inflammation and CVD risk in the paediatric popula-
tion and compare the levels of these markers with the
presence or absence of genetic variants. For this reason,
we assessed the association of 52 SNPs spanning the
FTO gene, with obesity in Spanish children; we also esti-
mated the influence of these SNPs in anthropometric,
clinical and metabolic parameters as well as inflamma-
tory and CVD risk markers.
Methods
Study design
The present study was designed as a case–control multi-
centre study in children. We recruited 534 children, 292
classified as obese according to body mass index (BMI),
using the age- and sex-specific cut-off points of Cole et al.
[17] (149 boys and 143 girls), and 242 as normal-BMI (135
boys and 107 girls). The children were prepubertal and
pubertal aged 6–15 years and were recruited in two cities
of Spain (Cordoba and Santiago de Compostela) from pri-
mary care centres and schools. Inclusion criterions were
European descent and the absence of congenital metabolic
diseases. Exclusion criterions were non-European descent,
the presence of congenital metabolic diseases, for example,
diabetes or hyperlipidaemia, or undernutrition and the use
of medication that alters blood pressure (BP) and glucose
or lipid metabolism. After assessments made on a first
visit to the school or primary care centre, the parents ofchildren fulfilling the inclusion criteria were invited to take
the children to the paediatrics unit of the participating
hospitals for a clinical examination.
Ethics statements
The protocol was performed in accordance with the
Declaration of Helsinki (Edinburgh 2000 revised) and fol-
lowing the recommendations of the Good Clinical Prac-
tice of the CEE (Document 111/3976/88 July 1990) and
the in force law of the Spanish regulation, that regulates
Clinical Trials in human beings (RD 223/04 about Clin-
ical Trials). The Ethics Committee on Human Research
of the University of Granada, the Ethics Committee of
the Reina Sof ía University Hospital of Cordoba and the
Bioethics Committee of the University of Santiago de
Compostela approved it. Written informed consent was
obtained from parents of children, and all children gave
their assent.
Anthropometric and biochemical measurements
Anthropometric measurements were taken by a single
examiner with the children barefoot and in their under-
wear. Body weight (kg) and height (cm) were measured
using standardized procedures, and waist circumference
(WC) was measured midway between the lowest rib and
the superior border of the iliac crest on standing subjects,
using an inelastic measuring tape at the end of normal ex-
piration. BMI was calculated as weight (kg) divided by the
square of the height (m2). BP was measured three times by
the same examiner, using a mercury sphygmomanometer
and following international recommendations. Blood sam-
ples were drawn via the antecubital vein after the patient
had fasted overnight. Insulin resistance was calculated by
means of the homeostatic model assessment of insulin re-
sistance (HOMA-IR). General biochemical analyses were
performed at the participating University Hospital Labora-
tories following internationally accepted quality control
protocols.
Cardiovascular and inflammatory biomarkers
Three different LINCOplexTM kits of human monoclonal
antibodies (Linco Research, St. Charles, MO) were used
on a Luminex® 200TM System (Luminex Corporation,
Austin, TX) to determine: 1) adiponectin (coefficient of
variation [CV]: 7.9%), resistin (CV: 6.0%) and active plas-
minogen activator inhibitor-1 (PAI-1) (CV: 6.6%) (Cat.
HADK1-61 K-A); 2) interleukin (IL)-6 (CV: 7.8%), IL-8
(CV: 7.9%), leptin (CV: 7.9%) and tumour necrosis factor
alpha (TNF-α) (CV: 7.8%) (Cat. HADK2-61 K-B); and 3)
soluble intercellular adhesion molecule 1 (sICAM-1) (CV:
7.9%), soluble endothelial selectin (sE-selectin) (CV:
11.2%), myeloperoxidase (MPO) (CV: 12.3%), matrix me-
talloproteinase 9 (MMP-9) (CV: 6.8%) and total PAI-1
(CV: 11.8%) (Cat. HCVD1-67 AK). C reactive protein
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turbidimetric immunoassay (PETIA) (Dade Behring Inc.,
Deerfield, IL).
DNA isolation and genotyping
Genomic DNA was extracted from peripheral white blood
cells (buffy coat) using the QIAamp Blood kit (Qiagen,
Valencia, CA) according to the manufacturer instructions.
52 SNPs in the FTO gene were selected. SNPs eligibility
was based on their location, first selecting every missense
variation and then others located in the promoter, 3′UTR
and 5′UTR regions with a minor allele frequency (MAF)
higher than 0.05 in the European descent population from
the NCBI database and a minimum pair wise LD of r2 =
0.8 for the selection of TagSNPs from the HapMap. In
addition, SNPs described to be positively associated with
obesity in relevant publications were also included. Geno-
typing was performed by the Illumina GoldenGate Assay
(Illumina Inc., San Diego, CA) on 96-well format Sentrix®
arrays. Two hundred fifty nanograms of DNA samples
were used per assay. Genotyping of the 52 SNPs resulted
in a success rate >97%. Five SNPs (rs1125337, rs9929152,
rs16952649, rs8053966 and rs8054364), which devia-
ted from Hardy-Weinberg equilibrium in the normal-
BMI group (p < 0.05) were excluded from the analysis
(Additional file 1: Table S1). Because our population pro-
ceeds from two different cities of Spain, we performed a
meta-analysis with the two populations as independent
groups to avoid problems like population stratification
or genotyping batch effect. The result of this analysis
(p values of Q Cochrane: rs9939609 Q = 0.967, rs9935401
Q = 0.888, rs9930333 Q = 0.795, rs9928094 Q = 0.867 and
rs8061518 Q = 0.926) indicate little detectable heterogen-
eity for the two considered populations of the study.
Statistical analysis
All continuous variables were expressed as mean ± SEM.
After checking for skewness and kurtosis, insulin,
HOMA-IR, total cholesterol, MMP-9 and total PAI-1 were
normalized using logarithmic transformation. Homogen-
eity of variances was estimated using the Levene test.
Comparisons between obese and normal-BMI children
variables were assessed using the Student’s t-test for un-
paired samples using SPSS (version 15.0.1. Chicago, IL).
Genotype and allele frequencies were calculated for cases
and controls. The genotypic relative risk was assessed by
comparing the obese and normal-BMI group, calculating
the odds ratio (OR) and 95% confidence interval (CI),
using logistic regression analysis under an additive model
adjusted by sex and age with a Bonferroni correction using
the SNPassoc package from R software [18]. Logistic or
linear regressions analysis in the entire population was
performed under an additive model to estimate the associ-
ations of each SNP with phenotypic parameters related toobesity as well as biomarkers of CVD risk and inflamma-
tion, adjusted by sex and age using the PLINK software.
Haplotype analysis involved the use of Haploview version
4.2 software and haplo.stats package from R software. Lo-
gistic regression analyses was performed to assess the as-
sociation of the studied haplotypes with obesity; the model
generated computes a χ2 to estimate the p value that test
the fit of the model. This p explains the variation in the
phenotype compared to a model with no effect. Signifi-
cance was considered at the level of p < 0.05.
Results
General characteristics of the population
Table 1 shows the anthropometric, clinical and meta-
bolic characteristics of obese and normal-BMI subjects.
Weight, height, BMI, BMI z-score and WC were signifi-
cantly higher in the obese compared with the normal-
BMI children. Systolic and diastolic BP, as well as
plasma triacylglycerols, apolipoprotein B (ApoB), insulin,
and HOMA-IR, were higher in obese children, whereas
plasmatic total cholesterol, high-density lipoprotein-
cholesterol (HDL-c) and apolipoprotein A1 (ApoA1) were
lower in obese children. Fasting plasma glucose and low-
density lipoprotein-cholesterol (LDL-c) concentrations did
not show differences between groups. Plasmatic resistin
and leptin concentrations were significantly higher in
obese than in normal-BMI subjects, by contrast decreased
levels of adiponectin were found in obese children. Inflam-
matory and CVD risk biomarkers were different between
groups. CRP, IL-6, IL-8 and TNF-α were significantly
higher in the obese group compared with those in the
normal-BMI group. Likewise, plasmatic sICAM-1, sE-
selectin, MPO and active and total PAI-1 were higher in
the obese group, whereas MMP-9 levels did not show dif-
ference between groups.
Association of SNPs with obesity
Five SNPs of the 52 included in the analysis were devi-
ated from Hardy-Weinberg equilibrium in the normal-
BMI group (p < 0.05). Those SNPs were excluded from
the association analysis. Of the 47 SNPs, five were asso-
ciated with obesity in children, adjusted by age and sex
under an additive model after Bonferroni correction; the
rs9935401, rs9939609, rs9928094 and rs9930333 located
in the intron 1 were positively associated with obesity,
whereas the rs8061518 in the intron 3 was negatively as-
sociated (Table 2).
Association of SNPs with obesity-related traits
Table 3 shows the association of the rs9939609 with obes-
ity relate-traits. MMP-9 was the only biomarker associated
with the former SNP after adjustment for sex, age and
BMI [β = 0.03 μg/l; 95% CI: (0.0004, 0.0690] (p = 0.048).
Table 1 Anthropometric, clinical and biochemical




Sex (M/F) 135/107 149/143 0.273
Age (y) 9.73 ± 0.2 9.43 ± 0.2 0.172
Weight (kg) 32.9 ± 0.7 55.9 ± 1.0 <0.001
Height (m) 1.37 ± 0.01 1.41 ± 0.01 0.001
BMI (kg/m2) 17.14 ± 0.13 27.56 ± 0.24 <0.001
BMI z-score −0.17 ± 0.04 3.49 ± 0.08 <0.001
Waist circumference (cm) 60.2 ± 0.5 84.0 ± 0.9 <0.001
Clinical and metabolic biomarkers
Systolic BP (mm Hg) 97 ± 1 111 ± 1 <0.001
Diastolic BP (mm Hg) 60 ± 1 69 ± 1 <0.001
Glucose (mg/dl) 84 ± 0 85 ± 1 0.772
Insulin (mU/l) 5.95 ± 0.23 11.46 ± 0.51 <0.001
HOMA-IR 1.26 ± 0.05 2.43 ± 0.12 <0.001
Triacylglycerols (mg/dl) 55 ± 1 75 ± 2 <0.001
ApoAI (mg/dl) 150 ± 2 132 ± 1 <0.001
ApoB (mg/dl) 67 ± 1 71 ± 1 0.008
Cholesterol (mg/dl) 171 ± 2 165 ± 2 0.012
HDL-c (mg/dl) 64 ± 1 51 ± 1 <0.001
LDL-c (mg/dl) 94 ± 2 97 ± 1 0.144
Adiponectin (mg/l) 28.28 ± 0.77 22.57 ± 0.66 <0.001
Resistin (μg/l) 9.65 ± 0.33 11.71 ± 0.34 <0.001
Leptin (μg/l) 4.30 ± 0.26 22.91 ± 0.86 <0.001
Inflammatory biomarkers
C-reactive protein (mg/l) 0.48 ± 0.07 1.99 ± 0.16 <0.001
Interleukin 6 (ng/l) 4.50 ± 0.53 6.95 ± 0.75 0.012
Interleukin 8 (ng/l) 1.57 ± 0.11 2.16 ± 0.15 0.003
TNF-α (ng/l) 3.06 ± 0.11 4.01 ± 0.13 <0.001
Cardiovascular disease risk biomarkers
MMP-9 (μg/l) 79.99 ± 3.15 88.42 ± 3.90 0.636
MPO (μg/l) 13.10 ± 1.16 21.51 ±1.70 <0.001
sE selectin (μg/l) 22.93 ± 0.76 31.26 ± 1.05 <0.001
sICAM-1 (mg/l) 0.153 ± 0.004 0.175 ± 0.005 <0.001
Active PAI-1 (μg/l) 5.16 ± 0.27 11.96 ± 0.57 <0.001
Total PAI-1 (μg/l) 18.95 ± 0.85 27.23 ± 1.01 <0.001
M: male; F: female; BMI: body mass index; BP: blood pressure; HOMA-IR:
homeostasis model assessment for insulin resistance; Apo: apolipoprotein;
HDL-c: high-density lipoprotein cholesterol; LDL-c: low-density lipoprotein
cholesterol; TNF-α: tumor necrosis factor alpha; MMP-9: metalloproteinase-9;
MPO: myeloperoxidase; sICAM-1: soluble intracellular adhesion molecule-1,
PAI-1: plasminogen activator inhibitor.
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obesity are included in the Additional file 1: Tables S2–S4.
Table 4 shows the association of the rs8061518 with
obesity relate-traits. Genotype with the minor allele of
this variant was negatively associated with leptin after
adjustment for age, sex and BMI [β = −1.38 μg/l (95%
CI: -2.70, -0.06)] (p = 0.041).
Linkage disequilibrium and haplotype block analysis
Figure 1 shows the LD of two well-defined haplo-blocks. In
this figure, we can observe the LD between the 5 SNPs sig-
nificantly associated with obesity. rs9928094, rs9930333,
rs9935401 and rs9939609 are in LD between each other,
while rs8061518 is in LD with no one of the above. Table 5
shows the total population haplotype blocks frequency as
well as cases and controls separately. The haplo-block 1
involves the SNPs rs9928094, rs9930333, rs10852521,
rs11075986, rs9935401 and rs9939609. The overall p value
of χ2 for association with obesity for this haplo-block was
8.72 × 10-4. The risk for obesity associated with the haplo-
type GGCCAA (which include the risk allele of rs9939609-
A and the risk alleles of the rs9928094-G, rs9930333-G
and rs9935401-A all of them in LD with the former)
was 1.26 (95% CI: 1.64 - 2.14) (p = 5.11 × 10-5). The
haplo-block 2 involves the SNPs rs3826169, rs8061518,
rs17818902 and rs7190053. The overall p value of χ2 for
association with obesity for this haplo-block was 0.026.
The risk for obesity associated with the haplotype
TGTC (the only one that include the rs8061518-G
allele, that showed a negative association with obesity)
was 0.65 (95% CI: 0.47 – 0.92) (p = 0.002).
Discussion
In the present study, where we studied 52 FTO variants
spanning the whole gene, we validate the positive associ-
ation of rs9939609 with obesity in Spanish children. We
found three other SNPs (rs9935401, rs9928094, and
9930333), also localized in the first intron of the gene
positively associated with obesity. Additionally, we ob-
served for the first time, the association of rs8061518, lo-
calized in the third intron of the gene, with a reduced
risk of obesity and low plasma leptin concentrations.
Our results are in concordance with many studies,
which have shown the association of the rs9939609 with
adulthood and childhood obesity [3,19], as well as other
SNPs in LD with it, such as the rs9935401, rs9928094 and
rs9930333 [16,20,21]. Several studies among European
descent population have demonstrated the association of
variant rs9939609 with anthropometric parameters, such
as BMI, weight, WC [22] and skin folds [23]. Interestingly,
the association with BMI found in carriers of haplotype
GGCCAA (which include the risk alleles of the SNPs posi-
tively associated with obesity) could be useful for the early
identification of inherited susceptibility to weight-gain
Table 2 Genotypic distribution of the FTO analysed polymorphisms and its association with obesity
Case Control Minor Allele
Polymorphism Allele 1/allele 2 11 12 22 11 12 22 Minor allele Case Control OR (95% CI) P P corr*
rs12445162 G/A 253 39 0 203 37 2 A 0.066 0.085 0.63 (0.35 - 1.11) 0.108 1
rs11075986 C/G 249 42 1 200 38 4 G 0.075 0.097 1.07 (0.80 - 1.44) 0.630 1
rs7203521 A/G 110 143 39 90 116 36 G 0.381 0.388 0.93 (0.68 - 1.28) 0.667 1
rs1861868 A/G 85 155 52 63 118 60 G 0.453 0.494 0.78 (0.58 - 1.06) 0.108 1
rs11643744 A/G 157 117 18 123 104 14 G 0.268 0.278 0.86 (0.61 - 1.22) 0.404 1
rs9928094 A/G 67 149 75 88 114 40 G 0.511 0.398 1.66 (1.22 - 2.24) 0.0009 0.018
rs9930333 T/G 67 150 74 87 112 41 G 0.511 0.398 1.64 (1.21 - 2.22) 0.001 0.023
rs10852521 C/T 104 139 49 64 116 61 T 0.410 0.496 0.67 (0.49 - 0.90) 0.008 0.327
rs7205986 A/G 68 151 72 70 111 61 G 0.505 0.483 0.78 (0.46 - 1.34) 0.369 1
rs9935401 G/A 72 150 69 95 111 33 A 0.419 0.370 1.76 (1.29 - 2.41) 0.0003 0.004
rs9939609 T/A 72 149 69 90 118 33 A 0.491 0.377 1.73 (1.26 - 2.37) 0.0006 0.009
rs3826169 T/C 170 102 20 151 81 10 C 0.245 0.210 1.32 (0.92 - 1.89) 0.132 1
rs8061518 A/G 159 107 22 95 108 32 G 0.262 0.365 0.56 (0.40 - 0.78) 0.0006 0.025
rs17818902 T/G 162 107 22 145 84 13 G 0.261 0.227 1.19 (0.84 - 1.67) 0.329 1
rs7190053 C/T 190 87 13 165 67 7 T 0.196 0.172 1.21 (0.82 - 1.78) 0.338 1
rs2111114 A/G 175 107 10 151 81 9 G 0.219 0.203 1.19 (0.82 - 1.74) 0.362 1
rs8044353 G/A 259 31 1 219 23 0 A 0.056 0.047 1.21 (0.61 - 2.39) 0.589 1
rs10521303 C/A 91 151 48 64 133 42 A 0.400 0.436 0.84 (0.62 - 1.15) 0.284 1
rs1558756 C/T 86 152 54 69 132 41 T 0.441 0.443 1.14 (0.83 - 1.57) 0.421 1
rs16952623 T/C 215 72 3 181 58 2 C 0.134 0.128 0.98 (0.62 - 1.56) 0.930 1
rs16952624 C/T 289 1 0 242 0 0 T 0.002 0.000 1
rs2111113 G/C 247 45 0 208 30 2 C 0.079 0.068 1.00 (0.56 - 1.78) 0.996 1
rs10852525 G/A 229 59 1 194 41 5 A 0.105 0.105 0.89 (0.55 - 1.45) 0.641 1
rs7194336 G/T 98 144 50 63 131 48 T 0.418 0.470 0.74 (0.55 - 1.01) 0.053 1
rs7203181 C/A 142 111 39 101 109 32 A 0.329 0.356 0.88 (0.65 - 1.19) 0.412 1
rs6499656 G/C 218 67 7 189 48 5 C 0.140 0.121 1.30 (0.84 - 2.03) 0.237 1
rs7191513 G/A 98 145 49 82 110 50 A 0.418 0.441 0.96 (0.72 - 1.30) 0.805 1
rs7194907 T/C 81 153 57 65 105 67 C 0.458 0.509 0.87 (0.64 - 1.18) 0.370 1
rs8056299 A/G 104 140 47 77 116 49 G 0.402 0.441 0.84 (0.62 - 1.14) 0.255 1
rs17225435 A/G 225 61 6 194 46 2 G 0.122 0.104 1.51 (0.93 - 2.46) 0.093 1
rs8049235 G/A 100 156 34 91 108 43 A 0.383 0.396 1.01 (0.74 - 1.59) 0.930 1
rs7199716 C/T 101 146 44 91 116 35 T 0.402 0.384 0.91 (0.67 - 1.24) 0.547 1
rs13334214 C/T 178 102 6 155 71 13 T 0.198 0.204 1.07 (0.74 - 1.57) 0.710 1
rs7194243 C/T 180 93 19 147 87 8 T 0.227 0.214 0.82 (0.57 - 1.18) 0.295 1
rs1136002 T/C 135 130 27 109 111 22 C 0.316 0.320 0.90 (0.66 - 1.24) 0.529 1
rs4784351 A/G 154 113 20 122 96 16 G 0.268 0.275 0.92 (0.65 - 1.28) 0.612 1
rs2540781 C/A 225 54 13 190 47 5 A 0.136 0.119 0.87 (0.57 - 1.32) 0.507 1
rs8049933 C/T 231 52 7 195 41 4 T 0.115 0.103 0.83 (0.52 - 1.32) 0.425 1
rs1558687 C/T 169 107 15 134 92 14 T 0.233 0.250 0.94 (0.67 - 1.33) 0.738 1
rs2075202 T/G 277 14 1 231 11 0 G 0.026 0.023 0.69 (0.25 - 1.88) 0.469 1
rs7200579 C/G 257 33 2 216 25 1 G 0.065 0.055 0.91 (0.50 - 1.68) 0.772 1
rs697771 C/T 102 137 53 72 127 43 T 0.413 0.443 1.00 (0.74 - 1.36) 0.985 1
rs12596638 G/A 221 66 4 176 61 5 A 0.126 0.150 0.99 (0.64 - 1.53) 0.979 1
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Table 2 Genotypic distribution of the FTO analysed polymorphisms and its association with obesity (Continued)
rs1008400 C/T 81 148 61 67 132 43 T 0.469 0.451 0.97 (0.71 - 1.32) 0.860 1
rs12932373 C/T 214 76 2 175 61 3 T 0.136 0.139 0.77 (0.49 - 1.21) 0.261 1
rs2689248 C/A 79 153 59 64 113 63 A 0.463 0.492 0.79 (0.59 - 1.07) 0.124 1
rs17833492 C/A 140 127 24 106 112 23 A 0.296 0.322 0.88 (0.63 - 1.22) 0.437 1
CI: confidence interval; OR: odds ratio. The OR was adjusted for age and sex under the additive model. *P values after Bonferroni correction. SNPs are ordered
according to their genomic position.
Table 3 Association of rs9939609 with anthropometric, clinical, inflammation and CVD risk biomarkers in children
Biomarkers TT AT AA β (95% CI) P Pa
n 162 267 102
Anthropometric factors
Height (m) 1.38 ± 0.01 1.39 ± 0.01 1.40 ± 0.02 −0.003 (−0.01, 0.00) 0.148 0.594
Weight (kg) 42.3 ± 1.4 45.6 ± 1.1 50.1 ± 2.2 3.31 (1.52, 5.10) 0.001 0.397
BMI (kg/m2) 21.69 ± 0.48 22.89 ± 0.36 24.51 ± 0.64 1.32 (0.59, 2.05) 0.001 –
BMI z-score 1.48 ± 0.16 1.86 ± 0.13 2.32 ± 0.22 0.45 (0.19, 0.71) 0.001 –
Waist circumference (cm) 70.58 ± 1.39 72.85 ± 0.99 77.46 ± 1.71 3.35 (0.61, 6.10) 0.017 0.487
Clinical and metabolic biomarkers
Systolic BP (mm Hg) 104 ± 1 104 ± 1 107 ± 1 1.14 (−0.71, 2.99) 0.227 0.466
Diastolic BP (mm Hg) 63 ± 1 65 ± 1 66 ± 1 1.24 (−0.26, 2.74) 0.106 0.888
Glucose (mg/dl) 85 ± 1 84 ± 0 84 ± 1 −0.47 (−1.34, 0.39) 0.286 0.143
Insulin (mU/l) 8.82 ± 0.64 8.73 ± 0.43 9.78 ± 0.71 0.02 (−0.01, 0.05) 0.253 0.225
HOMA-IR 1.89 ± 0.15 1.85 ± 0.10 2.07 ± 0.16 0.02 (−0.02, 0.05) 0.345 0.181
Triacylglycerols (mg/dl) 67 ± 3 64 ± 2 68 ± 4 0.07 (−3.90, 4.03) 0.974 0.216
ApoAI (mg/dl) 142 ± 2 141 ± 2 135 ± 3 −3.01 (−6.36, 0.34) 0.079 0.457
Cholesterol (mg/dl) 169 ± 3 166 ± 2 170 ± 2 0.002 (−0.01, 0.01) 0.721 0.540
HDL-c (mg/dl) 57 ± 1 57 ± 1 55 ± 1 −0.94 (−2.76, 0.89) 0.316 0.509
Adiponectin (mg/l) 25.89 ± 0.95 25.13 ± 0.74 24.16 ± 1.10 −0.72 (−2.18, 0.73) 0.331 0.934
Resistin (μg/l) 10.33 ± 0.44 10.81 ± 0.35 11.43 ± 0.55 0.55 (−0.15, 1.25) 0.125 0.384
Leptin (μg/l) 13.57 ± 1.23 14.37 ± 0.83 16.29 ± 1.52 1.38 (−0.43, 3.18) 0.135 0.149
Inflammatory biomarkers
C-reactive protein (mg/l) 2.08 ± 0.29 2.21 ± 0.23 2.77 ± 0.53 0.37 (−0.14, 0.88) 0.153 0.743
IL-6 (ng/l) 5.61 ± 0.90 6.00 ± 0.69 6.19 ± 1.05 0.42 (−0.96, 1.80) 0.550 0.759
IL-8 (ng/l) 1.86 ± 0.16 1.95 ± 0.15 1.83 ± 0.21 0.03 (−0.25, 0.30) 0.853 0.783
TNF-α (ng/l) 3.53 ± 0.16 3.66 ± 0.13 3.33 ± 0.20 −0.02 (−0.27, 0.23) 0.875 0.308
Cardiovascular disease risk biomarkers
MMP-9 (μg/l) 80.39 ± 4.35 83.62 ± 3.70 92.82 ± 6.05 0.03 (0.00, 0.07) 0.049 0.048
MPO (μg/l) 17.56 ± 2.06 17.84 ± 1.61 17.65 ± 1.88 0.29 (−2.80, 3.38) 0.853 0.636
sE-Selectin (μg/l) 26.34 ± 1.14 28.22 ± 1.05 26.64 ± 1.40 0.66 (−1.25, 2.56) 0.500 0.711
sICAM-1 (mg/l) 0.162 ± 0.005 0.168 ± 0.004 0.158 ± 0.006 0.001 (−0.01, 0.01) 0.997 0.645
Active PAI-1 (μg/l) 8.35 ± 0.58 8.61 ± 0.52 10.35 ± 0.97 0.85 (−0.19, 1.89) 0.109 0.946
Total PAI-1 (μg/l) 23.22 ± 1.34 22.21 ± 0.92 26.84 ± 2.09 0.02 (−0.02, 0.06) 0.359 0.994
CI: Confidence interval; BMI: body mass index; BP: blood pressure; HOMA-IR: homeostasis model assessment for insulin resistance; HDL-c: high-density lipoprotein
cholesterol; IL: interleukin; TNF-α: tumour necrosis factor alpha; MMP-9: matrix metalloproteinase-9; MPO: myeloperoxidase; sICAM-1: soluble intracellular adhesion
molecule-1, PAI-1: plasminogen activator inhibitor. β Coefficients represent the change in absolute traits values of each additional risk allele. General linear models
were used to examine associations, P adjusted by age and sex, Pa adjusted by age, sex, and BMI.
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Table 4 Association of rs8061518 with anthropometric, clinical, inflammation and CVD risk biomarkers in children
Biomarkers AA AG GG β (95% CI) P Pa
N 254 215 54
Anthropometric factors
Height (m) 1.39 ± 0.01 1.40 ± 0.01 1.39 ± 0.02 −0.001 (−0.01, 0.00) 0.613 0.107
Weight (kg) 46.8 ± 1.2 44.9 ± 1.3 42.6 ± 2.4 −2.44 (−4.35, -0.54) 0.012 0.130
BMI (kg/m2) 23.70 ± 0.38 22.33 ± 0.42 21.48 ± 0.81 −1.27 (−2.05, -0.50) 0.001 –
BMI z-score 2.16 ± 0.14 1.61 ± 0.14 1.36 ± 0.30 −0.45 (−0.72, -0.17) 0.001 –
Waist circumference (cm) 74.74 ± 1.07 71.99 ± 1.18 71.10 ± 2.25 −1.70 (−4.63, 1.22) 0.254 0.534
Clinical and metabolic biomarkers
Systolic BP (mm Hg) 106 ± 1 103 ± 1 104 ± 2 −1.74 (−3.69, 0.21) 0.080 0.758
Diastolic BP (mm Hg) 66 ± 1 64 ± 1 61 ± 1 −2.23 (−3.80, -0.65) 0.006 0.083
Glucose (mg/dl) 85 ± 0 84 ± 0 85 ± 1 −0.11 (−1.02, 0.80) 0.816 0.836
Insulin (mU/l) 9.52 ± 0.48 8.56 ± 0.48 8.17 ± 1.13 −0.05 (−0.09, -0.02) 0.003 0.153
HOMA-IR 2.02 ± 0.10 1.80 ± 0.11 1.79 ± 0.30 −0.05 (−0.09, -0.02) 0.003 0.153
Triacylglycerols (mg/dl) 68 ± 2 63 ± 2 66 ± 6 −2.33 (−6.52, 1.86) 0.276 0.995
ApoAI (mg/dl) 141 ± 2 137 ± 2 145 ± 4 0.15 (−3.40, 3.71) 0.932 0.330
Cholesterol (mg/dl) 166 ± 2 168 ± 2 172 ± 4 0.01 (−0.004, 0.02) 0.223 0.287
HDL-c (mg/dl) 57 ± 1 56 ± 1 58 ± 2 0.07 (−1.87, 2.01) 0.945 0.107
Adiponectin (mg/l) 25.46 ± 0.77 23.92 ± 0.73 27.90 ± 1.81 0.38 (−1.15, 1.91) 0.628 0.741
Resistin (μg/l) 11.34 ± 0.40 10.30 ± 0.33 10.37 ± 0.72 −0.68 (−1.42, 0.06) 0.074 0.227
Leptin (μg/l) 16.98 ± 1.02 12.57 ± 0.85 11.21 ± 1.70 −3.55 (−5.43, -1.66) <0.001 0.041
Inflammatory biomarkers
C-reactive protein (mg/l) 2.50 ± 0.26 2.26 ± 0.31 1.70 ± 0.30 −0.34 (−0.89, 0.20) 0.217 0.784
IL-6 (ng/l) 5.62 ± 0.64 6.56 ± 0.90 4.71 ± 0.91 0.09 (−1.36, 1.53) 0.905 0.705
IL-8 (ng/l) 1.94 ± 0.14 1.98 ± 0.17 1.57 ± 0.19 −0.10 (−0.39, 0.19) 0.495 0.804
TNFα (ng/l) 3.62 ± 0.14 3.51 ± 0.14 3.60 ± 0.27 −0.05 (−0.32, 0.22) 0.711 0.696
Cardiovascular disease risk biomarkers
MMP-9 (μg/l) 82.62 ± 3.42 86.21 ± 4.14 84.12 ±8.05 0.01 (−0.03, 0.04) 0.764 0.754
MPO (μg/l) 19.19 ± 1.68 16.65 ± 1.44 16.55 ± 4.26 −1.63 (−4.94, 1.68) 0.336 0.712
sE-Selectin (μg/l) 28.19 ± 0.98 26.13 ± 1.08 26.61 ± 2.34 −1.09 (−3.13, 0.95) 0.296 0.924
sICAM-1 (mg/l) 0.165 ± 0.004 0.168 ± 0.005 0.155 ± 0.007 −0.002 (−0.01, 0.01) 0.605 0.923
Active PAI-1 (μg/l) 9.81 ± 0.62 8.45 ± 0.49 6.16 ± 0.63 −1.71 (−2.80, -0.62) 0.002 0.067
Total PAI-1 (μg/l) 24.74 ± 1.11 22.56 ± 1.16 20.66 ± 1.85 −0.04 (−0.08, 0.003) 0.073 0.350
CI: Confidence Interval; BMI: body mass index; BP: blood pressure; HOMA-IR: homeostasis model assessment for insulin resistance; HDL-c: High-density lipoprotein-
cholesterol; IL: interleukin; TNFα: tumour necrosis factor alpha; MMP-9: matrix metalloproteinase-9; MPO: myeloperoxidase; sICAM-1: soluble intracellular adhesion
molecule-1; PAI-1: plasminogen activator inhibitor-1. β coefficients represent the change in absolute traits values of each additional risk allele. General linear
models were used to examine associations, P adjusted by age and sex, Pa adjusted by age, sex, and BMI.
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than considering the effect of a single marker.
Among the large number of phenotypes measured in
this study, we did not find any significant association with
FTO variants located in the first intron after additional
adjustment for BMI, except in the case of MMP-9, a well-
known biomarker of CVD risk [24], which has shown
an association not only with rs9939609 but also with
rs9928094 and rs9930333. The association of rs9939609
with CVD markers are opposed in the scientific literature.Whereas some have shown significant association with
low HDL-c [25,26] and high triacylglycerols [25], others
[27,28] have not found any association. Additionally, there
are few studies that link CVD and FTO gene [29,30], and
to our knowledge, there are no studies that have included
CVD risk biomarkers as MPO, sE-selectin, sICAM-1, PAI-
1 and MMP-9 as we did here. Some other studies have
shown the association of rs9939609 with inflammatory
biomarkers as in the case of Timpson et al. [31] and Fisher
et al. [32]; both found a positive association with CRP.
Figure 1 Linkage disequilibrium structure in terms of r2 of 10 SNPs genotyped, representing two well-defined haplo-blocks.
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IL-6, IL-1β, IL-10, IL-18 or TNF α, and found no signifi-
cant association in line with our findings. The fact that the
majority of studies has failed to associate the FTO variants
with obesity related trait, indicates that this gene is in
a very close relationship with obesity and fat mass. The
potential effect on the obesity-related traits seems indirect
and dependent on BMI changes.Table 5 Association analysis of obesity with FTO
haplotypes combinations
Haplotypes Frequency
All Case Control OR (95% CI) P
Block 1
ATTCGT 0.437 0.401 0.481 Reference
GGCCAA 0.425 0.483 0.355 1.26 (1.64 - 2.14) 5.11 × 10-5
ATCGGT 0.080 0.073 0.087 0.99 (0.63 - 1.57 ) 0.413
GGCCGT 0.025 0.019 0.031 0.65 (0.29 - 1.45) 0.133
Block 2
CATC 0.223 0.237 0.207 Reference
TGTC 0.297 0.258 0.345 0.65 (0.47-0.92) 0.002
TATC 0.212 0.225 0.196 1.02 (0.71-1.45) 0.231
TAGT 0.179 0.193 0.163 1.02 (0.70-1.51) 0.217
TAGC 0.053 0.063 0.041 1.29 (0.70 - 2.38) 0.143
Block 1 involves SNPs: rs9928094, rs9930333, rs10852521, rs11075986,
rs9935401, and rs9939609, Overall p value: 8.72 × 10-4. Block 2 involves SNPs:
rs3826169, rs8061518, rs17818902, and rs7190053. Overall p value: 0.026.
OR: odds ratio; CI: confidence interval.The association of the variant rs9939609 with MS has
been shown in European [25] and mixed population
[34]. Furthermore, rs1421085 which is highly correlated
(LD r2 = 0.931) [3] with rs9939609, was associated with
MS in an independent study [35]. On the contrary,
rs9939609 was not associated with MS in Japanese [36]
or Indian [37] population. As we discussed previously,
some studies showed an association with cardiovascular
markers, also related to MS, whereas others did not. The
same is true for glucose metabolism and BP; some stud-
ies found a significant association with glucose and insu-
lin [38] and others, in concordance with our work, did
not [26-28]. In the case of BP, neither Freathy et al. [25]
nor Kring et al. [26] observed an association; however,
Pausova et al. [39] did otherwise with systolic BP in ado-
lescents. Moreover, a recent genome-wide scan identified
an association between rs9930333 (SNP in LD with
rs9939609) and BP in adolescents [40]. In our study
population, the percentage of MS in the obese group
was 9.8%, and we did not observe association of any
SNPs with MS (data not shown). These results could be
due to the small size of the study population as it has
been reported that sample sizes of at least 12000 are re-
quired to observe association between FTO genotype
and metabolic traits that are secondary to changes in BMI
[25]. In addition, the lack of association found in our study
might also be due to the age of our population (mean of
9.6 years), because it has been demonstrated that
rs9939609 showed changes in its association with BMI as
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no association at age of 4 years, but this association be-
came increasingly stronger at ages 7–11 years [41]; other
study, observed a biphasic change in the associations of
this variant with BMI, strengthening with age up to a peak
at age 20 years, and then weakening with increasing adult
age [42].
Beyond the replication of association found in SNPs
within the first intron, we interestingly identified a novel
SNP (rs8061518), localized in the third intron of the gene
about 40–60 kb away from the originally reported SNPs in
the first intron, which was associated with reduced risk of
obesity. This SNP was also negatively associated with some
MS traits, leptin and aPAI-1. Although our results should
be validated in larger independent studies, we used the
publicly available GIANT consortium published data [43],
and we found that the rs8061518 was associated with BMI
with a p = 0.0149 in a population of 123844 European
descent adults, and the association effect was in the same
direction that we observed in our population. Only one
previous study in Sorb population [44] has demonstrated
that other SNPs in the same region of the gene were associ-
ated with reduced risk of obesity, among them the stron-
gest effect on BMI values was associated with rs17818902.
However, in the present study we did not confirm this asso-
ciation, in concordance with Dlouha et al. who genotyped
this SNP in a group of 2559 unrelated European descent
population [45]. In addition, no association of this variant
with BMI was found in the GIANT consortium (p =
0.206). One possible explanation of this is that the
rs17818902 represents a second mutational event segre-
gating in the Sorbian population.
The haplotype analysis shows that a unique haplotype
TGTC (haplo-block 2) with the minor allele of the
rs8061518 exhibited a decreased risk for obesity. These
results indicate that there may be other regions beyond
the intron 1 in the FTO gene associated with being lean
or obese that needs to be studied.
The association of the FTO gene with leptin has also
been studied. Labayen et al. [9], Rutters et al. [14], and
Zimmerman et al. [33] found a positive association of the
rs9939609 with leptin, whereas Do et al. [23] did it with
the rs17817449; however, this association was abolished
after adjusting for BMI. In our population, we did not
observe an association in the case of the rs9939609,
but interestingly we found a negative association with
rs8061518 that remains significant after adjustment by
sex, age and BMI. Leptin, a hormone produced mainly by
the white adipose tissue, is clearly associated with the total
amount of body fat and secondly with BMI. It participates
in the regulation of a range of biological functions and
process including energy intake and expenditure, neuroen-
docrine system, autonomic function, reproduction, and
glucose homeostasis [46,47]. As this hormone is involvedin three different pathways [47], its mechanisms of action
act through different signalling pathways. Studies in ani-
mals [48] and humans [49] have demonstrated that it can
exert its action independently of obesity. Then, it might be
the case in the association of this adipokine with the
rs8061518; however, further studies are needed to clarify
this aspect.
Our study has several strengths and limitations to
highlight. The strengths are the high quantity of bio-
markers measured in the children, the genotyping of
several SNPs along the FTO gene and the way of SNPs
election. We selected part of the SNPs from a group
with a MAF higher than 0.05 in the European descent
population from the NCBI database to make an associ-
ation case–control study as complementary strategy to
GWAS in the identification of gene variants associated
with obesity and its comorbidities. The limitations are
first, the sample size of the current investigation is rela-
tively small for a genetic association with metabolic
traits. Second, there are a number of environmental fac-
tors known to influence body weight in children, which
were not taken into account in this study. Furthermore,
information on body composition, nutrition and phys-
ical activity, which are strongly associated factors with
body-weight regulation, was not available. Fat compos-
ition data could be valuable for the adjustment of the
association of rs8061518 with leptin in order to clarify
the role of the genetic variant on obesity.
Conclusion
We confirmed the previously reported association of
genetic variability in intron 1 of the FTO gene with the
risk of obesity and without association with other related
traits of inflammation and CVD risk biomarkers. We
also have observed strong statistical evidence for an as-
sociation of rs8061518 in intron 3 of the gene with de-
creased risk of obesity and low concentration of leptin.
Additionally, both studied haplo-blocks, that included
the significant associated SNPs, were also associated
with the risk of obesity. Our findings provide qualified
support for the notion that a detailed examination of the
third intron region of the FTO gene in larger independ-
ent studies should provide valuable clues to the molecu-
lar mechanisms by which sequence variation in this
region affects clinical phenotypes.Additional file
Additional file 1: Table S1. Description of the genotyped polymorphisms.
Table S2. Association of rs9928094 with biomarkers of inflammation and
cardiovascular disease risk in obese children. Table S3. Association of
rs9930333 with biomarkers of inflammation and cardiovascular disease risk in
obese children. Table S4. Association of rs9935401 with biomarkers of
inflammation and cardiovascular disease risk in obese children.
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